The 5 analysts offering 12-month price forecasts for Verrica Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 25.00 and a low estimate of 17.00. The median estimate represents a +69.35% increase from the last price of 11.81.
The current consensus among 5 polled investment analysts is to Buy stock in Verrica Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.40
Reporting Date Mar 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.